FY2024 EPS Estimate for Nurix Therapeutics Lifted by Analyst

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Nurix Therapeutics in a research report issued on Monday, October 21st. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($2.80) for the year, up from their prior forecast of ($2.87). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Nurix Therapeutics’ Q4 2024 earnings at ($0.67) EPS, Q1 2025 earnings at ($0.67) EPS, Q2 2025 earnings at ($0.69) EPS, Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.73) EPS and FY2025 earnings at ($2.81) EPS.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Friday, October 11th. The company reported ($0.67) EPS for the quarter, hitting the consensus estimate of ($0.67). The company had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%.

Other equities research analysts have also issued reports about the stock. Royal Bank of Canada decreased their target price on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Jefferies Financial Group assumed coverage on Nurix Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $41.00 price target for the company. JPMorgan Chase & Co. lifted their price target on Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Barclays lifted their price target on Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Finally, Truist Financial assumed coverage on Nurix Therapeutics in a research note on Wednesday, July 31st. They set a “buy” rating and a $36.00 price target for the company. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.40.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX opened at $25.22 on Wednesday. Nurix Therapeutics has a one year low of $4.22 and a one year high of $26.43. The company’s fifty day moving average is $23.95 and its two-hundred day moving average is $19.84.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,490 shares of Nurix Therapeutics stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $51,468.30. Following the completion of the sale, the chief financial officer now owns 54,479 shares in the company, valued at $1,126,080.93. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,408 shares of Nurix Therapeutics stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $70,443.36. Following the completion of the sale, the insider now owns 45,150 shares in the company, valued at $933,250.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Houte Hans Van sold 2,490 shares of Nurix Therapeutics stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $51,468.30. Following the completion of the sale, the chief financial officer now owns 54,479 shares of the company’s stock, valued at $1,126,080.93. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,105 shares of company stock worth $1,507,181 in the last 90 days. 7.20% of the stock is owned by company insiders.

Institutional Trading of Nurix Therapeutics

A number of institutional investors have recently modified their holdings of the company. Redmile Group LLC grew its holdings in shares of Nurix Therapeutics by 37.7% during the 1st quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock worth $65,900,000 after purchasing an additional 1,226,497 shares during the period. Driehaus Capital Management LLC purchased a new stake in shares of Nurix Therapeutics during the 2nd quarter worth about $26,778,000. Candriam S.C.A. grew its holdings in shares of Nurix Therapeutics by 30.5% during the 2nd quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock worth $24,297,000 after purchasing an additional 272,136 shares during the period. Affinity Asset Advisors LLC grew its holdings in shares of Nurix Therapeutics by 12.6% during the 2nd quarter. Affinity Asset Advisors LLC now owns 912,000 shares of the company’s stock worth $19,033,000 after purchasing an additional 101,747 shares during the period. Finally, Millennium Management LLC grew its holdings in shares of Nurix Therapeutics by 60.2% during the 2nd quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock worth $12,514,000 after purchasing an additional 225,374 shares during the period.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.